article thumbnail

Is DTC pharma advertising coming to an end?

PharmaVoice

Biggest spenders DTC ads are almost exclusively leveraged for brand name drugs, with two-thirds of that spending concentrated on just 39 drugs between 2016 and 2018, according to a Government Accountability Office report. Some of the biggest spenders are shelling out millions to get their brands in front of American audiences.

article thumbnail

9 Sneaky Thyroid Toxins Hiding in Your Home

The Thyroid Pharmacist

10] Its not only found in obvious sources like plastic containers and packaging, but also in the lining of canned foods and drinks, receipts, toys, electronics, and household items. When grocery shopping, try to purchase items that are packaged in glass and canned foods that are packaged with BPA-free lining. 2016;13(11):1153.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TekniPlex Healthcare Unveils New Barrier Protection Systems Plant

Pharmaceutical Commerce

Supporting sterile barrier packaging and supply chain resilience The Madison plant reinforces the TekniPlex Healthcare’s goal of assisting pharma and medical companies, which indirectly includes its downstream partners as well.

article thumbnail

Can rare disease research in the US thrive under the new administration?

Pharmaceutical Technology

At BIO, David Ridley, a health economist at Duke University, said based on the reauthorisation experience in 2016, the program is likely to be renewed, but in the meantime, “this is slowing down drug development by a couple of years for many of these drugs.” “I How will RFK Jr’s American dream for vaccines play out?

FDA
article thumbnail

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

J&J gained prostate cancer rights for Zejula from Tesaro in 2016, the latter company was acquired by GSK. How will RFK Jr’s American dream for vaccines play out? Akeega combines the active ingredients in GSK’s PARP inhibitor Zejula (niraparib) and J&J’s androgen blocker Zytiga (abiraterone).

article thumbnail

Biopharma's costly blind spot: Exhausted minds, expensive mistakes

pharmaphorum

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

Given that multiple work packages may often start or end together, or else take longer than others ( Figure 1 ), the introduction of new PAT requires assessment and planning by multiple departments. Figure 1 : Process analytical technology implementation in (bio)pharmaceutical GMP manufacturing. References 1. Bliesner DM.